Masimo (NASDAQ:MASI) Releases FY25 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY25 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $4.90-$5.10 for the period, compared to the consensus estimate of $4.74.

Masimo Stock Up 3.6 %

MASI opened at $172.07 on Thursday. The firm’s fifty day moving average price is $168.86 and its two-hundred day moving average price is $139.54. The company has a market capitalization of $9.21 billion, a P/E ratio of 118.67 and a beta of 1.01. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $180.97. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.63 earnings per share. On average, analysts anticipate that Masimo will post 4.03 EPS for the current year.

Wall Street Analyst Weigh In

MASI has been the subject of a number of recent analyst reports. Piper Sandler upped their price objective on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Wells Fargo & Company lifted their price objective on shares of Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Raymond James raised their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $179.67.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.